E-cadherin and beta-catenin are down-regulated in prostatic bone metastases.
Bryden, A A G Hoyland, Judith A Freemont, Anthony J Clarke, Noel W Schembri Wismayer, D George, Nicholas J
Bryden, A A G
Hoyland, Judith A
Freemont, Anthony J
Clarke, Noel W
Schembri Wismayer, D
George, Nicholas J
Citations
Altmetric:
Abstract
OBJECTIVE: To determine the E-cadherin and beta-catenin expression phenotype in untreated primary prostate cancer and corresponding bone metastases. MATERIALS AND METHODS: Paired bone metastasis and primary prostate specimens were obtained from 14 men with untreated metastatic prostate carcinoma. The tumours were histologically graded by an independent pathologist. Expression of mRNA for E-cadherin and beta-catenin was detected within the tumour cells using in-situ hybridization with a 35S-labelled cDNA probe. The expression of E-cadherin and beta-catenin were graded as uniform, heterogeneous or negative. RESULTS: The mRNA for E-cadherin was expressed in 13 of 14 primary carcinomas and 11 bone metastases; beta-catenin was expressed by 13 and nine, respectively. Of the primary tumours, nine expressed E-cadherin and beta-catenin uniformly; in contrast, all metastases had down-regulated E-cadherin and/or beta-catenin. CONCLUSIONS: The down-regulation of E-cadherin and beta-catenin are a feature of the metastatic phenotype, which may be a significant factor in the genesis of bone metastases. However, this does not appear to be reflected in the expression of these molecules in the primary tumours.
Description
Date
2002-03
Publisher
Collections
Keywords
Bone Cancer
Prostatic Cancer
Prostatic Cancer
Type
Article
Citation
E-cadherin and beta-catenin are down-regulated in prostatic bone metastases. 2002, 89 (4):400-3 BJU Int.